Form SC 13G/A Mylan N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
S&P Affirms Ratings on Mylan (MYL) Following Meda AB Acquisition Announcement
February 12, 2016 8:10 AM ESTStandard & Poor's Ratings Services said it affirmed its 'BBB-' corporate credit rating and all existing issue-level ratings on Mylan N.V. (Nasdaq: MYL). The outlook is stable.
Mylan has announced it is acquiring Sweden-based pharmaceutical maker Meda AB for $9.9 billion, which includes the debt at Meda. The acquisition adds more than $2 billion in annual sales of generic, branded, and over-the-counter drugs to Mylan, strengthens its European franchise, and expands Mylan into a several new territories.
"Although the transaction, funded with... More
